TrovaGene Inc. TROV is leaving no stone unturned to make its Precision Cancer Monitoring (PCM) platform a success in the global markets. In an endeavour to expand PCM’s reach, the company recently set up a European subsidiary – Trovagene Research Institute (TRI) – which will be headed by prominent researcher Alberto Bardelli.
TrovaGene also landed a partnership with the Department of Oncology at the University of Torino – which is currently associated with Bardelli. We believe that the collaboration with this renowned university and appointment of Bardelli as the head of TRI will boost PCM’s take-up among European oncologists and researchers.
Meanwhile, TrovaGene continues to present and publish positive data from the clinical studies of the PCM platform. At the 16th World Conference on Lung Cancer held in Denver, the company presented data that demonstrated PCM’s effectiveness in detecting EGFR T790M mutations in urinary circulating tumor DNA (ctDNA), which can result in better management of the disease.
TrovaGene’s PCM indentified EGFR T790M resistance mutations much earlier than radiologic detection of progression in patients. Through daily monitoring of urinary ctDNA, PCM helped in identifying patients who respond to anti-EGFR therapy considerably earlier than follow-up CT-scans.
Notably, TrovaGene’s non-invasive, cell-free technology is cost efficient. We feel that the technology can be ancillary to the current standard of tissue biopsy. It can also be performed in patients incapable of undergoing a tissue biopsy.
We believe that there is significant market opportunity for TrovaGene which is presently an important player in urine-based liquid biopsy platforms. On the flip side, the technology is relatively at an early stage, which implies that it will take some time before accelerated adoption begins.
Zacks Rank & Key Picks
Currently, TrovaGene carries a Zacks Rank #4 (Sell). Better-placed stocks in the medical sector include Masimo MASI, NuVasive NUVA and Thoratec THOR. All the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
THORATEC CORP (THOR): Free Stock Analysis Report
MASIMO CORP (MASI): Free Stock Analysis Report
NUVASIVE INC (NUVA): Free Stock Analysis Report
TROVAGENE INC (TROV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research